SFRP1 is a known antagonist of the Wnt pathway and inhibits WNT-dependent transcription, leading to a decrease in the intracellular level of β-catenin (Wnt activator) [58] Importantly, a deregulated Wnt signalling pathway is implicated in cancer progression, stemness, multidrug resistance, and immune escape [59]. The gene discussed is SFRP1; the disease is cancer.